Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy—A Retrospective Registry-Based Cohort Study

Paschal Ruggajo1,2*, Einar Svarstad2,3†, Sabine Leh2,4†, Hans-Peter Marti2,3†, Anna Varberg Reisæther5,6†, Bjørn Egil Vikse2,7○

1 Department of Internal Medicine, MUHAS, Dar es Salaam, Tanzania, 2 Department of Clinical Medicine, University of Bergen, Bergen, Norway, 3 Department of Medicine, Haukeland University Hospital, Bergen, Norway, 4 Department of Pathology, Haukeland University Hospital, Bergen, Norway, 5 Medical Birth Registry of Norway, Norwegian Institute of Public Health, Bergen, Norway, 6 Department of Transplantation Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway, 7 Department of Medicine, Haugesund Hospital, Haugesund, Norway

† These authors contributed equally to this work.
○ These authors also contributed equally to this work.
* prugajo@yahoo.com

Abstract

Background

Low Birth Weight (LBW) is a surrogate for fetal undernutrition and is associated with impaired nephron development in utero. In this study, we investigate whether having been born LBW and/or small for gestational age (SGA) predict progression to ESRD in IgA nephropathy (IgAN) patients.

Study Design

Retrospective registry-based cohort study.

Settings & Participants

The Medical Birth Registry has recorded all births since 1967 and the Norwegian Renal Registry has recorded all patients with ESRD since 1980. Based on data from the Norwegian Kidney Biopsy Registry we included all patients diagnosed with IgAN in Norway from 1988–2013. These registries were linked and we analysed risk of progression to ESRD associated with LBW (defined as birth weight less than the 10th percentile) and/or SGA (defined as birth weight less than the 10th percentile for gestational week) by Cox regression statistics.

Results

We included 471 patients, of whom 74 developed ESRD. As compared to patients without LBW, patients with LBW had a hazard ratio (HR) of 2.0 (95% confidence interval 1.1–3.7) for the total cohort, 2.2 (1.1–4.4) for males and 1.3 (0.30–5.8) for females. Corresponding HRs for SGA were 2.2 (1.1–4.2), 2.7 (1.4–5.5) and 0.8 (0.10–5.9). Further analyses showed that as compared to patients with neither LBW nor SGA, patients with either SGA or LBW
did not have significantly increased risks (HRs of 1.3–1.4) but patients who were both LBW and SGA had an increased risk (HR 3.2 (1.5–6.8).

**Limitation**

Mean duration of follow-up only 10 years and maximum age only 46 years.

**Conclusion**

Among IgAN patients, LBW and/or SGA was associated with increased risk for progression to ESRD, the association was stronger in males.

---

### Introduction

Brenner hypothesized in 1988 that adverse intrauterine environment, for example due to placental insufficiency or maternal malnutrition, was associated with impaired nephron development and increased risk of hypertension and progressive kidney disease in adult life[1]. Low birth weight (LBW) is the most accessible marker of adverse intrauterine environment[1] and studies have shown strong associations with fewer and larger glomeruli[2,3], increased risk of hypertension [4,5], albuminuria [6,7] and progressive chronic kidney disease[8,9]. It is possible that SGA, defined as low birth weight for gestational age, is a better marker for adverse intrauterine environment and studies have shown associations with lower GFR [10,11]. Previous studies have suggested LBW, SGA and preterm birth to be associated with reduced estimated and measured GFR [12–14].

IgA nephropathy (IgAN) is the most frequently occurring primary idiopathic glomerulonephritis worldwide [15–17]. The clinical phenotype of IgAN range from stable and asymptomatic to chronic and progressive renal failure [18–20] and several studies have investigated clinical and histopathological variables as risk factors for progressive disease [21–25]. Due to its chronic course it is possible to look upon IgAN as a model disease for chronic kidney disease in general and the advantages of this might be that IgAN patients generally are younger, have fewer confounding comorbidities while on the other hand having a high rate of progressive disease. Specifically, for the investigation of the Brenner hypothesis, better access to birth related data in these younger patients is also of benefit. As described above, LBW might be a risk factor for progressive IgAN as LBW is associated with fewer and larger glomeruli [2,3]. Indeed a previous study by Tsuboi et al demonstrated that lower glomerular density predicted the long-term prognosis of IgAN[26]. Also in support of this, low birth weight was associated with higher rates of progressive disease in a small study of children with IgAN[27]. More and larger studies are however needed to explore this further.

In the present study we used data from Norwegian Registries and analyzed whether adverse birth-weight related variables are associated with development of end-stage renal disease (ESRD) in patients diagnosed with IgAN in Norway in the period 1988–2013. We first analyzed whether LBW predicted progression to ESRD, but also analyzed the effects of SGA and preterm birth, and combinations of these factors. Our main hypothesis was that LBW and SGA predict progression to ESRD, in line with the Brenner hypothesis.

### Material and Methods

Since 1967, the Medical Birth Registry of Norway has registered extensive medical data on all births in Norway (total population of 5.1 million) [28]. The form is completed by the attending midwife and doctor. Since 1980, the Norwegian Renal Registry has registered data on all
patients in Norway who develop ESRD (defined as starting chronic dialysis treatment or undergoing renal transplantation). The Norwegian Kidney Biopsy Registry has registered clinical and morphologic data for all patients who have had a kidney biopsy performed in Norway since 1988. All kidney biopsies in this study were evaluated by an experienced nephropathologist. The data from all registries were available until December 2013 and data were linked using the 11-digit unique national identification number.

We included all patients diagnosed with IgA nephropathy in the Norwegian Kidney Biopsy Registry between 1988 and 2013 and who were born in Norway after 1967 and had their birth data registered in the Medical Birth Registry. The study was approved by the Regional Ethics Committee of Norway. Patient records/information was anonymized and de-identified prior to analysis. This investigation abides to Declaration of Helsinki.

**Exposure Variables**

LBW was defined as birth weight less than the 10th percentile for gender (2930g for male; 2690g for female). Based on total data from the Medical Birth Registry, different cut-offs were tested in separate analyses (For male and female gender respectively the 25th percentile was defined as 3233g and 3050g, the 20th percentile as 3168g and 2960g, the 15th percentile as 3070g and 2910g and the 7.5th percentile as 2860g and 2640g). From 1967 through 1998, gestational age was based on the last menstrual period and from 1999 onward on routine ultrasonographic examination in gestational weeks 17 through 20. Preterm birth was defined as a gestational age less than 37 weeks. Based on national data on birth weight, gestational week, gender and plurality, a z-score denoting standard deviation from mean of birth weight for each week of gestational age was calculated for each patient by the Medical Birth Registry [29,30]. Small for gestational age (SGA) was defined as birth weight less than the 10th percentile for gestational week in the study population (defined by z-score less than -1.2900 for male and -1.5280 for female gender). In separate analyses, different cut-offs for birth weight for gestational age (defined by z-score), separately for gender, were tested. The respective z-scores for males and females for the 25th percentile were defined as -0.7400 and -0.9600, for 20th percentile as -0.8680 and -1.1620, for 15th percentile as -1.1120 and -1.3360 and for 7.5th as -1.5000 and -1.6620. Maternal preeclampsia was defined as increased BP and proteinuria after 20 weeks of gestation (BP ≥140/90) [31].

Recorded standard clinical and laboratory tests were performed at the time of kidney biopsy. Estimated glomerular filtration rate (eGFR) was calculated using the IDMS-traceable CKD-EPI equation [32] using the serum creatinine values (unit micromoles/L, converted to mg/L for eGFR calculation) recorded at the time of biopsy (All patients were assumed to be of white race). The CKD-EPI is calculated as: eGFR = 141 x Min (Serum Creat/k,1)\(^{0.7} \times \text{Max(Serum Creat/k,1)}\)^{-1.209} x 0.993\(^{\text{Age}}\) x 1.018 (if female); where k = 0.7 for females and 0.9 for males, \(\alpha = 0.329\) for females and 0.411 for males [33]. For patients who had a kidney biopsy performed before year 2005, their serum creatinine levels were reduced by 5% to standardize them to IDMS-traceable levels [33]. For use in the present study we defined three categories of eGFR as: >60, 30–60 and <30 ml/min/1.73m\(^2\). Proteinuria had been registered as grams per 24 h, grams per litre and milligrams per millimole creatinine and as stix results. Estimates for proteinuria per 24h were calculated as described previously [34], three categories of <1, 1–3 and > = 3 grams/24h were used in the analyses. Systolic blood pressure was reported in three categories based on blood pressure level: <140, 140–159 or > = 160 mmHg, cut-offs for diastolic BP were 90 and 100 mmHg. The following histopathological parameters were used; proportion of sclerosed glomeruli, proportion of glomeruli with crescents (cellular or fibrocellular), grade of interstitial fibrosis (categorized as mild, moderate or severe if the fibrosis involved <25%,}
25–50% or more than 50% of the cortical area respectively) and grade of tubular atrophy which was (categorized as mild, moderate or severe if the tubular atrophy involved <25%, 25–50% or more than 50% of the cortical area). Treatment data (type of medications, dose and duration) were not available, see discussion for a description of standard treatment in Norway.

Outcome Variables
The outcome was development of ESRD defined as the date of starting chronic dialysis treatment or undergoing renal transplantation. Individuals who did not develop ESRD were followed until December 31, 2013.

Statistical Analyses
Data were analysed in a cohort design with birth-weight related variables as exposure and ESRD as outcome variables. Hazard ratio estimates associated with selected risk factors for ESRD were obtained by Cox regression analyses. Assumptions of proportional hazard were tested by log-minus-log plots and the assumptions were met. Analyses were performed for the total cohort, but also separately for male and female. Associations between birth weight related variables and clinical and histopathological variables at time of biopsy were investigated but in the present paper we did not focus on the effects of the latter variables on risk of ESRD as these have been thoroughly described previously[35]. Due to low number of endpoints, we chose to only perform adjusted analyses for eGFR. The analyses were performed with the statistical package SPSS 21 (SPSS, Chicago, IL). Unless otherwise noted, values are reported as means (standard deviation) or hazard ratio estimates (95% confidence intervals). P-values < 0.05 were considered statistically significant, and all tests were two tailed.

Results
A total of 471 patients (70.8% males) were included in our study, of whom 74 (15.7%) developed ESRD. Mean age at biopsy was 23.8 (7.7) years, mean duration of follow-up after biopsy was 10.3 (6.7) (range 0.08–25.8) years, mean age at ESRD was 29.3 (7.0) years and mean age at end of follow-up for those who did not develop ESRD was 35.1 (8.1) years. Of the included patients, 10.2% were categorized as having had LBW and 9.6% as SGA.

At the time of kidney biopsy, IgAN patients born with LBW or SGA had comparable clinical and pathological characteristics as those born without LBW (Table 1). When the same analysis was repeated gender-wise, males had significantly higher systolic blood pressure (132 mmHg vs 123 mmHg, p-value < 0.001) and diastolic blood pressure (80 mmHg vs 76 mmHg, p-value 0.01) than females. There was no gender difference observed in the other clinicopathological characteristics, including estimated GFR. As expected, patients born with LBW or SGA more often were born preterm, patients born SGA also had a statistically significant higher likelihood of being born in a preeclamptic pregnancy.

In separate analyses of male and female patients, SGA was significantly associated with higher urinary protein excretion (3.0 vs 1.9 gram/24h; p = 0.04) in males but not females. Analyses for other clinical and histopathological variables at the time of biopsy showed no significant associations. Comparing clinicopathological characteristics in Table 1 between those with both LBW and SGA to those with neither of them showed no significant differences.

As expected from previous studies [35], patients who developed ESRD had lower eGFR, higher blood pressure, higher urinary protein excretion and higher grade of interstitial fibrosis or tubular atrophy and had a higher risk of developing ESRD. The present study does not focus on these data, but for completeness, details are given in S1 Table and S2 Table.
Birth weight related variables and the risk of developing ESRD

Compared to patients with birth weight above the 10th percentile, LBW was significantly associated with higher risk of developing ESRD, HR 2.0 (95% CI 1.1–3.7; p = 0.03) (Table 2). Similarly, SGA was also significantly associated with ESRD; HR 2.2 (1.2–4.2); p = 0.02).

When the analyses were done separately for male and female patients, both SGA and LBW remained statistically significant predictors of ESRD in males, but there was no excess risk in females (Table 2 and Figs 1 and 2). After adjustments for eGFR, neither LBW nor SGA were significantly associated with risk of ESRD. A similar analysis for preterm birth, showed a non-significant higher risk of ESRD for the total cohort and for both gender subgroups.

To explore these associations further, we analyzed risk of developing ESRD by decremental birth weight and birth weight according to the gestational age (Table 3). In these analyses we categorized birth weight and birth weight for gestational age below 25th, 20th, 15th, 10th and 7.5th percentile cut-offs. For birth weight, the hazard ratio was statistically significant for the 15th and 10th percentile but not significant for the 7.5th percentile. For birth weight for gestational age, the hazard ratio increased with lower cut-off and was statistically significant for the 10th and 7.5th percentile cut-off, the hazard ratio was highest when using the 7.5th percentile. A separate analysis using a cut-off of 2.5 kg (conforming to the WHO global LBW threshold) showed hazard ratio of 1.0 (0.31–3.1) for the total cohort, 1.24 (0.30–5.1) for males and 0.81 (0.11–6.1) for females; however, analysis using this cut-off value was limited by the low number of patients (only 20 patients had birth weight less than 2.5 kg, of whom 3 developed ESRD).

### Table 1. Cohort characteristics at the time of IgAN diagnosis stratified by Low Birth Weight and Small for Gestational Age, Norway 1967–2013.

| Clinicopathological characteristics | LBW | SGA |
|------------------------------------|-----|-----|
|                                   | No  | Yes | No  | Yes |
| N (%) male                         | 298 (70.4) | 34 (70.8) | 283 (69.9) | 32 (71.1) |
| Age (years)                        | 23.8±7.6 | 24.7±8.6 | 23.8±7.7 | 25.6±8.3 |
| Systolic BP (mmHg)                 | 129.1±21.0 | 128.8±20.7 | 128.7±21.4 | 130.3±18.2 |
| Diastolic BP (mmHg)                | 78.5±14.1 | 77.6±14.6 | 78.5 ± 14.4 | 76.6 ±13.0 |
| eGFR (ml/min/1.73m²)              | 100.2±50.1 | 92.4±38.5 | 100.7±50.8 | 87.7±38.3 |
| Urinary protein (g/d)             | 2.0±2.4 | 2.6±2.6 | 2.0±2.5 | 2.6±2.8 |
| Proportion sclerosed glomeruli (%) | 0.1±0.2 | 0.1±0.2 | 0.1±0.2 | 0.1±0.2 |
| Proportion with glomerular crescents (%) | 1.5±6.0 | 1.1±3.1 | 1.4±5.8 | 1.9±5.6 |
| Grade of interstitial fibrosis b   | 0.8±0.7 | 1.0±0.7 | 0.8±0.7 | 0.8±0.8 |
| Grade of tubular atrophy c        | 0.7±0.8 | 0.9±1.0 | 0.7±0.8 | 0.8±0.9 |
| Pre-eclampsia in the mother (%)   | 7 (1.7) | 3 (6.3) | 3 (0.7) | 6 (13.3) a |
| N (%) birth weight <10th percentile (LBW) | 0% | 100% (by def.) | 18(4.4) | 24 (53.3) a |
| N (%) gestational age <37 weeks   | 8 (2.0) | 19 (41.3) | 24 (5.9) | 3 (6.7) |
| N (%) birth weight <7.5th percentile for gestational age (SGA) | 19 (4.7) | 26 (56.5) | 0% | 100% (by def.) |

a p<0.001
b Grade of interstitial fibrosis was categorized as mild, moderate or severe if the fibrosis involved <25%, 25–50% or more than 50% of the cortical area respectively.
c Grade of tubular atrophy was categorized as mild, moderate or severe if the tubular atrophy involved <25%, 25–50% or more than 50% of the cortical area respectively.
doi:10.1371/journal.pone.0153819.t001
From the analyses presented in Tables 2 and 3, SGA was associated with slightly higher hazard ratios for ESRD as compared to LBW. Preterm birth was on the other hand not associated with

### Table 2. Risk of ESRD according to whether the IgAN patients had LBW, SGA or preterm birth, separate analyses for male and female, Norway 1967–2013.

|                | N total | N ESRD | Unadjusted model | Adjusted model<sup>a</sup> |
|----------------|---------|--------|------------------|----------------------------|
|                |         |        | HR (95% CI)      | p-value                    |
| **Total**      | 471     | 74     |                  |                            |
| Not LBW        | 423     | 62     | 1.0 (ref)        | 1.0 (ref)                  |
| LBW            | 48      | 12     | 2.0 (1.1–3.7)    | 0.03                       |
| Not SGA        | 405     | 57     | 1.0 (ref)        | 1.0 (ref)                  |
| SGA            | 45      | 11     | 2.2 (1.1–4.2)    | 0.02                       |
| Not Preterm    | 423     | 62     | 1.0 (ref)        | 1.0 (ref)                  |
| Preterm        | 27      | 6      | 1.5 (0.65–3.5)   | 0.3                        |
| **Male**       |         |        |                  |                            |
| Not LBW        | 298     | 48     | 1.0 (ref)        | 1.0 (ref)                  |
| LBW            | 34      | 10     | 2.2 (1.1–4.4)    | 0.02                       |
| Not SGA        | 283     | 43     | 1.0 (ref)        | 1.0 (ref)                  |
| SGA            | 32      | 10     | 2.7 (1.4–5.5)    | 0.005                      |
| Not Preterm    | 295     | 48     | 1.0 (ref)        | 1.0 (ref)                  |
| Preterm        | 20      | 5      | 1.6 (0.64–4.0)   | 0.3                        |
| **Female**     |         |        |                  |                            |
| Not LBW        | 125     | 14     | 1.0 (ref)        | 1.0 (ref)                  |
| LBW            | 14      | 2      | 1.3 (0.30–5.8)   | 0.7                        |
| Not SGA        | 122     | 14     | 1.0 (ref)        | 1.0 (ref)                  |
| SGA            | 13      | 1      | 0.8 (0.10–5.9)   | 0.8                        |
| Not Preterm    | 128     | 14     | 1.0 (ref)        | 1.0 (ref)                  |
| Preterm        | 7       | 1      | 1.1 (0.14–8.4)   | 0.9                        |

<sup>a</sup>Adjusted for estimated Glomerular Filtration in 3 categories (i.e. > 60, 30–59 and < 30 ml/min respectively).

doi:10.1371/journal.pone.0153819.t002

### Single versus multiple adverse birth-weight related outcomes and risk of ESRD

From the analyses presented in Tables 2 and 3, SGA was associated with slightly higher hazard ratios for ESRD as compared to LBW. Preterm birth was on the other hand not associated with
Table 3. Risk of ESRD among IgAN patients analysed at different percentile cut-offs for birth weight and birth weight for gestational age.

| Birth weight percentile | N total | N ESRD | Unadjusted | Adjusted a | Birth weight for gestational age percentile d |
|------------------------|---------|--------|------------|------------|-------------------------------------------|
|                        |         |        | HR (CI)    | p-value    | HR (CI)                                  |
| ≥25th perc             | 352     | 52     | 1.0(ref)   | 1.0 (ref)  |                                                      |
| <25th perc             | 119     | 22     | 1.3(0.76–2.1) | 0.4     | 0.96(0.57–1.6) | 0.9 |
| ≥20th perc             | 377     | 53     | 1.0 (ref)  | 1.0 (ref)  |                                                      |
| <20th perc             | 94      | 21     | 1.7(1.0–2.8) | 0.05    | 1.2(0.69–2.0) | 0.5 |
| ≥15th perc             | 401     | 58     | 1.0 (ref)  | 1.0 (ref)  |                                                      |
| <15th perc             | 70      | 16     | 1.8(1.0–3.2) | 0.04    | 1.1(0.58–2.0) | 0.8 |
| ≥10th perc             | 423     | 62     | 1.0 (ref)  | 1.0 (ref)  |                                                      |
| <10th perc             | 48      | 12     | 2.0(1.1–3.7) | 0.03    | 1.4(0.69–2.7) | 0.4 |
| ≥7.5th perc            | 437     | 66     | 1.0 (ref)  | 1.0 (ref)  |                                                      |
| <7.5th perc            | 34      | 8      | 1.6(0.78–3.4) | 0.2     | 1.1(0.48–2.6) | 0.8 |

a Adjusted for estimated Glomerular Filtration in 3 categories (i.e. > 60, 30–60 and < 30 ml/min respectively)

b for males, birth weight percentile < 25th, <20th, <15th, <10th and <7.5th percentile was defined as < 3.2325 kg, 3.1680 kg, 3.0695 kg, 2.9300 kg and 2.8597 kg respectively; for females, corresponding birth weights were 3.0500 kg, 2.9600 kg, 2.9100 kg, 2.6900 kg and 2.6400 kg respectively.

c Identical analysis as in Table 2, included for completeness.

d for males, birth weight for gestational age z-scores corresponding to < 25th, <20th, <15th, <10th and <7.5th were -0.7400, -0.8680, -1.1120, -1.2900 and -1.5000 respectively. For females, corresponding z-scores were -0.9600, -1.1620, -1.3360, -1.5280 and -1.6620.

Fig 2. Cumulative Probability of ESRD in patients with IgAN according to whether or not the patient had SGA.

doi:10.1371/journal.pone.0153819.g002

doi:10.1371/journal.pone.0153819.t003
To explore this further, we analyzed the combined effect of SGA and/or LBW on the risk of developing ESRD (Table 4). In these analyses, patients who were either SGA or LBW had no increased risk, but patients who were both SGA and LBW had a significantly higher HR of 3.2 (1.5–6.8), p = 0.002 for the total cohort and a HR of 3.6 (1.6–8.2), p = 0.02 for males (Table 4), the number of patients in subgroups were however low and confidence intervals were wide.

Repeated analyses testing the combined effect of preterm birth and/or LBW showed that LBW in preterm birth was not associated with higher hazard ratio of ESRD than LBW in term birth [2.2(0.97–5.2) vs 2.1 (0.89–4.5)]. Identical analysis for the combined effect of preterm birth and/or SGA did on the other hand show a stronger effect of SGA in preterm as compared to term births [10.8 (2.6–45) vs 1.9 (0.93–3.1) (results not shown)].

| Table 4. Risk of ESRD among IgAN patients stratified by LBW, SGA or the combination of these, (gender-wise).|
|-----------------|---|---|---|---|---|
|                 | N total | N ESRD | Unadjusted model | Adjusted model a |
|                 |         |         | HR (95% CI) | p-value | HR (95% CI) a | p-value |
| **Total**       |         |         |             |         |             |         |
| Not SGA or LBW  | 385     | 53      | 1.0 (ref)   | 1.0 (ref) |
| SGA, not LBW    | 19      | 3       | 1.3 (0.39–4.0) | 0.7      | 0.74 (0.18–3.0) | 0.7      |
| Not SGA, LBW    | 20      | 4       | 1.4 (0.51–3.9) | 0.5      | 1.0 (0.36–2.8) | 1.0      |
| SGA and LBW     | 26      | 8       | 3.2 (1.5–6.8) | 0.002    | 2.0 (0.87–4.8) | 0.1      |
| **Male**        |         |         |             |         |             |         |
| Not SGA or LBW  | 270     | 40      | 1.0 (ref)   | 1.0 (ref) |
| SGA, not LBW    | 13      | 3       | 1.9 (0.57–6.0) | 0.3      | 0.89 (0.21–3.7) | 0.9      |
| Not SGA, LBW    | 13      | 3       | 1.6 (0.50–5.3) | 0.4      | 0.74 (0.22–2.5) | 0.6      |
| SGA and LBW     | 19      | 7       | 3.6 (1.6–8.2) | 0.002    | 1.8 (0.70–4.6) | 0.2      |
| **Female**      |         |         |             |         |             |         |
| Not SGA or LBW  | 115     | 13      | 1.0 (ref)   | 1.0 (ref) |
| SGA, not LBW    | 6       | 0       | 0.0         | 1.0      | 0.0         | 1.0      |
| Not SGA, LBW    | 7       | 1       | 1.0 (0.13–7.8) | 1.0      | 1.0 (0.14–8.1) | 1.0      |
| SGA and LBW     | 7       | 1       | 1.8 (0.23–13.6) | 0.6      | 2.2(0.28–17.1) | 0.5      |

a Adjusted for estimated Glomerular Filtration in 3 categories (i.e. > 60, 30–59 and < 30 ml/min respectively)

doi:10.1371/journal.pone.0153819.t004

development of ESRD. To explore this further, we analyzed the combined effect of SGA and/or LBW on the risk of developing ESRD (Table 4). In these analyses, patients who were either SGA or LBW had no increased risk, but patients who were both SGA and LBW had a significantly higher HR of 3.2 (1.5–6.8), p = 0.002 for the total cohort and a HR of 3.6 (1.6–8.2), p = 0.02 for males (Table 4), the number of patients in subgroups were however low and confidence intervals were wide.

Repeated analyses testing the combined effect of preterm birth and/or LBW showed that LBW in preterm birth was not associated with higher hazard ratio of ESRD than LBW in term birth [2.2(0.97–5.2) vs 2.1 (0.89–4.5)]. Identical analysis for the combined effect of preterm birth and/or SGA did on the other hand show a stronger effect of SGA in preterm as compared to term births [10.8 (2.6–45) vs 1.9 (0.93–3.1) (results not shown)].

**Discussion**

In this comprehensive, registry-based study, we have shown that LBW was significantly associated with increased risk of progression to ESRD in IgAN. Having been born SGA, indicating intrauterine growth restriction, was also associated with ESRD. These effects were significant in the total cohort and in males, but we could not find evidence of increased risk in females. Further analyses showed that patients with combined LBW and SGA have significantly increased risk of developing ESRD as compared to patients with only one of the markers. After adjustments for eGFR at time of diagnosis, the birth weight related variables were no longer associated with progression to ESRD.

As described in the introduction, previous studies have shown associations between birthweight related variables and increased risk for all-cause ESRD in the total population [8,36,37]. In a previous Norwegian study, LBW was also associated with higher risk of ESRD due to glomerular disease, of which IgAN was an important group [8]. The present study has added the information that LBW is a risk marker for progressive IgAN. This has to our knowledge never previously been shown in IgAN, although a previous study showed that children with IgAN
who were born with LBW had significantly higher proportion of sclerotic glomeruli than children with normal birth weight [27]. Another study indicated higher rates of relapsing minimal change disease in children born with LBW[38]. LBW is the most used marker of intrauterine growth retardation and has been shown to be associated with a reduced number of enlarged glomeruli [2,3,39], salt sensitivity of blood pressure [40,41], higher blood pressure [42,43], microalbuminuria and low glomerular filtration rate [11], all markers that could be associated with higher risk of progressive renal failure [44,45]. Taken together, this suggests that LBW may be strongly associated with increased rates of progressive renal disease.

During nephrogenesis, week 9 to 36 in utero, the number of formed nephrons correlates with increase in fetal weight. LBW is the most accessible marker of adverse intrauterine environment [1], birth weight may however be affected both by duration of gestation and rate of fetal growth [46]. A previous histomorphometric study deduces that about 260,000 nephrons are formed for every 1kg increase in fetal weight in utero [3]. It can also be calculated that about twenty thousand nephrons are formed per week of gestation, and of these about 60% are formed during the third trimester [47]. Prematurity leads to ‘oligonephropathy’ with quantitative and qualitative alteration of nephron formation [48] and also LBW and SGA are associated with reduced nephron numbers in humans [1]. SGA may be a better marker of intrauterine growth restriction as LBW at short gestational age may be physiologically normal. In a previous Norwegian study that investigated risk of all cause ESRD, LBW was associated with slightly higher hazard ratio of ESRD than SGA[8].

In this current study, SGA was on the other hand associated with slightly higher hazard ratio than LBW. The finding that SGA might be a strong risk marker have been indicated by previous studies demonstrating increased risk for development of renal disease and hypertension [49,50], lower renal drug clearance [12], having smaller kidneys at birth and impaired kidney growth in early childhood [51]. An important observation was however that patients born with both LBW and SGA had much higher risk for developing ESRD than those born with only SGA or LBW, patients with only one marker did not have a statistically significant increased risk. In this study, we did not observe any significant difference in clinicopathological characteristics when we compared those who had combined LBW and SGA to those who had neither of them. Zidar et al on the other hand found higher mean percentage of sclerotic glomeruli among those with previous IUGR [52]. Our study indicate that future studies of intrauterine growth restriction and adult renal disease need to investigate both the birth weight as well as the birth weight in relation to gestational age. Patients with both LBW and SGA and renal disease may also need closer follow-up.

In the paragraph above we discussed how a lower number of nephrons could represent a lower reserve capacity and predispose to progressive renal disease. It is however also possible that intrauterine nutritional imbalances could program immunological function or risk that may persist throughout life [53]. Previous studies have suggested that early life perturbations of the immune system may be associated with lifelong increased risk for autoimmune and allergic diseases as well as chronic inflammatory conditions such as diabetes, cardiovascular diseases, metabolic syndrome and cancer [54–56]. Furthermore, prolonged, impairment of cell-mediated immunity is more common among LBW infants [57]. In relation to kidney diseases, Hoy et al found that low birth weight in the aborigines in Australia predisposed to post-infectious glomerulonephritis [58], this could however also have been explained by higher rates of poverty which highly correlates with both malnutrition and increased susceptibility to infectious diseases. Using the same definition of LBW as in a previous population-based study by us, we found that 11.9% of our IgAN patients would be categorised as LBW [59]. This is slightly higher than the 9.9% in the previous study[59], but this was not statistically significant. Thus, IgAN patients seem to have the same prevalence of LBW as the population and this argues
against LBW being a significant risk marker for development of IgAN through immunological mechanisms.

Adjusted analysis showed that the association between LBW/SGA and progression to ESRD was lost after adjustments for eGFR. The most likely explanation for this is that eGFR is a much stronger risk factor for ESRD than LBW or SGA. It might however also imply that reduced GFR itself may be a consequence of being born SGA or LBW [12]. In the present study, males born with SGA had lower eGFR at time of diagnosis than males without SGA. It is still unclear whether LBW or SGA should be taken into consideration when treating patients with IgAN or planning studies of IgAN, but we would argue that more knowledge is needed and that there could be important effects that could be uncovered in larger or more targeted studies.

We observed that the association between LBW and increased risk of ESRD was significant and strong in males but not in females. Globally, gender distribution in IgA nephropathy varies widely in different populations with more preponderance towards male gender ranging from a male: female ratio of less than 2:1 in Japan [60] to 6:1 in the in Northern Europe [61–63]. Recent registry-based data on IgAN in Japan [64] and Korea [65] have shown no appreciable gender difference as contrasted to data from the Norwegian Kidney Biopsy Register in which male comprised of 74% of all IgAN cases [25]. This wide range however may in part reflect the observed difference in subjective clinical indications and thresholds of performing a kidney biopsy among nephrologists in different countries, or other genetic/environmental differences between different areas of the world that have no clinical explanation so far [66]. The statistical analysis in our analyses may however be polarized towards showing stronger effect in males due to compromised statistical power in females. Previous studies however, have suggested that females may be protected against the detrimental effects of LBW on progressive renal disease [67–69], although renal clearance studies could not show a clear effect modification on the associations between LBW and reduced renal function [12, 70, 71]. In the present study, it is possible that the observed gender difference could be attributed to smaller sample size and fewer endpoints for females, thus increasing risk of Type 2 statistical error and should thus be interpreted with caution.

The strengths of the present study are that the study is registry based with complete national inclusion, have prospective registration of birth weight related variables, investigates a clinically useful condition (IgAN) and has a clinically relevant and reliable end point (ESRD). A weakness was that data on death was not available for the cohort and patients could not be censored for death. Another weakness is that ESRD is a rare outcome and usually takes considerable time to develop, number of patients with endpoints were therefore low in some subgroups. As an inclusion criterion of the study was being born after 1967, we were only able to include a relatively young cohort of IgAN patients (mean age at biopsy was 24 years). Previous studies have shown that for IgAN patients younger than 60 years and elevated serum creatinine level > 2.0 mg/dl, young age correlated with poor prognosis [72, 73].

Another limitation is that we did not have information regarding the treatment the patients received, most patients were however treated by nephrologists and received standard international care with angiotensin inhibition for those with either high blood pressure or proteinuria since the 1990’s, steroid treatment have been increasingly used since the early 2000’s for those with proteinuria above 1 gr/24h and preserved kidney function after a trial period with angiotensin inhibition.

In conclusion, the present study has shown that birth-weight related variables were associated with risk for developing ESRD, the association was stronger in male patients who were the predominant gender of this cohort (mirroring global trends). Both LBW and SGA were important risk markers, but the combination of these were especially important. Our results support
the Brenner hypothesis. Future studies should investigate further the importance of SGA vs LBW and whether these markers are associated with altered renal morphology and risk of progression to ESRD also in other kidney diseases.

**Supporting Information**

S1 Table. Cohort characteristics at the time of IgAN diagnosis stratified by development of ESRD. (DOCX)

S2 Table. Clinical and histopathological characteristics at the time of biopsy and risk of ESRD. (DOCX)

**Acknowledgments**

Aspects of this work were presented as oral abstract on November 5th, 2015 at the ASN Kidney Week 2015, in San Diego, California, USA.

**Author Contributions**

Conceived and designed the experiments: PR BEV ES. Performed the experiments: PR BEV SL. Analyzed the data: PR BEV. Contributed reagents/materials/analysis tools: SL HPM AVR. Wrote the paper: PR BEV. Academic Supervisor of 1st Author (PR): BEV.

**References**

1. Luyckx VA, Brenner BM. Birth weight, malnutrition and kidney-associated outcomes [mdash] a global concern. Nature Reviews Nephrology 2015. 11:135–49. doi:10.1038/nrneph.2014.251 PMID: 25599618

2. Manalich R, Reyes L, Herrera M, Melendi C, Fundora I. Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. Kidney international 2000. 58:770–3. PMID: 10916101

3. Hughson M, Farris AB, Douglas-Denton R, Hoy WE, Bertram JF. Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney international 2003. 63:2113–22. PMID: 12733238

4. Hoy W, Hughson M, Singh G, Douglas-Denton R, Bertram J. Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney international 2006. 70:104–10. PMID: 16723986

5. Mu M, Wang S-F, Sheng J, Zhao Y, Li H-Z, Hu C-L, et al. Birth weight and subsequent blood pressure: a meta-analysis. Archives of cardiovascular diseases 2012. 105:99–113. doi:10.1016/j.acvd.2011.10.006 PMID: 22424328

6. Hoy WE, Rees M, Kile E, Mathews JD, Wang Z. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. Kidney international 1999. 56:1072–7. PMID: 10469376

7. White SL, Perkovic V, Cass A, Chang CL, Poulter NR, Spector T, et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. American Journal of Kidney Diseases 2009. 54:248–61. doi:10.1053/j.ajkd.2008.12.042 PMID: 19339091

8. Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease. Journal of the American Society of Nephrology 2008. 19:151–7. PMID: 18057216

9. Luyckx VA, Bertram JF, Brenner BM, Fall C, Hoy WE, Ozanne SE, et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. The Lancet 2013. 382:273–83.

10. Hallan S, Euser AM, Irgens LM, Finken MJJ, Holmen J, Dekker FW. Effect of intrauterine growth restriction on kidney function at young adult age: the Nord Trøndelag Health (HUNT 2) Study. American Journal of Kidney Diseases 2008. 51:10–20. PMID: 18155528
11. Keijzer-Veen MG, Schrevel M, Finken MJ, Dekker FW, Nauta J, Hille ET, et al. Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation. Journal of the American Society of Nephrology 2005. 16:2762–8. PMID: 15987756

12. Schreuder MF, Wilhelm AJ, Bökenkamp A, Timmermans SM, Delemarre-van de Waal HA, van Wijk JA. Impact of gestational age and birth weight on amikacin clearance on day 1 of life. Clinical Journal of the American Society of Nephrology 2009. 4:1774–8. doi:10.2215/CJN.02230409 PMID: 19713296

13. Bacchetta J, Harambat J, Dubourg L, Guy B, Liutkus A, Canterino I, et al. Both extrauterine and intrauterine growth restriction impair renal function in children born very preterm. Kidney international 2009. 76:445–52. doi:10.1038/ki.2009.201 PMID: 19516242

14. Keijzer-Veen MG, Kleinveld HA, Lequin MH, Dekker FW, Nauta J, de Rijke YB, et al. Renal function and size at young adult age after intrauterine growth restriction and very premature birth. American Journal of Kidney Diseases 2007. 50:542–51. PMID: 17900453

15. D’amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Qj Med 1987. 64:709–27.

16. Floege J, Feehally J. IgA nephropathy: recent developments. Journal of the American Society of Nephrology 2000. 11:2201–7. PMID: 10773058

17. Levy M, Berger J. Worldwide perspective of IgA nephropathy. American Journal of Kidney diseases 1988. 12:340–7. PMID: 3055955

18. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. American Journal of Kidney Diseases 2012. 59:865–73. doi:10.1053/j.ajkd.2012.02.326 PMID: 22497792

19. Canetta PA, Kiryluk K, Appel GB. Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clinical Journal of the American Society of Nephrology 2014. 9:617–25. doi:10.2215/CJN.07260713 PMID: 24071652

20. Wyatt RJ, Julian BA. IgA nephropathy. New England Journal of Medicine 2013. 368:2402–14. doi:10.1056/NEJMra1206793 PMID: 23782179

21. Alamartine E, Sabatier J-C, Guerin C, Berliet J-M, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. American journal of kidney diseases 1991. 18:12–9. PMID: 2063844

22. Chacko B, John GT, Neelakantan N, Korula A, Balakrishnan N, Kirubakaran MG, et al. Presentation, prognosis and outcome of IgA nephropathy in Indian adults. Nephrology Dialysis Transplantation 2009. 24:3068–74.

23. Knoop T, Vikse BE, Svarstad E, Leh S, Reisaeter AV, Bjørneklett R. Mortality in patients with IgA nephropathy. American Journal of Kidney Diseases 2013. 62:883–90. doi:10.1053/j.ajkd.2013.04.019 PMID: 23796906

24. Tsuboi N, Kawamura T, Koike K, Okonogi H, Hamaguchi A, et al. Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clinical Journal of the American Society of Nephrology 2010. 5:39–44. doi:10.2215/CJN.04680709 PMID: 19965542

25. Zidar N, Čavić M, Kenda RB, Koselj M, Ferluga D, et al. Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children. Nephron 1998. 79:28–32. PMID: 9609458

26. Ingens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta obstetricia et gynecologica Scandinavica 2000. 79:439–5. PMID: 10857866

27. Skjærven R, GJESSING HK, BAKKETEIG LS. Birthweight by gestational age in Norway. Acta obstetricia et gynecologica Scandinavica 2000. 79:440–9. PMID: 10857867

28. Tsuboi N, Kawamura T, Koike K, Okonogi H, Hirano K, Hamaguchi A, et al. Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clinical Journal of the American Society of Nephrology 2010. 5:39–44. doi:10.2215/CJN.04680709 PMID: 19965542

29. Glinianaia SV, Skjærven R, Magnus P. Birthweight percentiles by gestational age in multiple births: A population-based study of Norwegian twins and triplets. Acta obstetricia et gynecologica Scandinavica 2000. 79:450–8. PMID: 10857868

30. Dahlstrom BL, Ellström Engh M, Bukholm G, Øian P. Changes in the prevalence of pre-eclampsia in Akershus County and the rest of Norway during the past 35 years. Acta obstetricia et gynecologica Scandinavica 2006. 85:916–21. PMID: 16862468
32. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. Jama 2012. 307:1941–51. doi: 10.1001/jama.2012.3954 PMID: 22570462

33. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine 2009. 150:604–12. PMID: 19414839

34. Vikse BE, Hallan S, Bostad L, Leivestad T, Iversen BM. Previous preeclampsia and risk for progression of biopsy-verified kidney disease to end-stage renal disease. Nephrology Dialysis Transplantation 2010.gfq169.

35. Knoop T, Vågane A, Vikse BE, Svarstad E, Magnusdottir BT, Leh S, et al. Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy. American journal of nephrology 2015. 41:210–9. doi: 10.1159/000381403 PMID: 25872002

36. Lackland DT, Egan BM, Fan ZJ, Syddall HE. Low Birth Weight Contributes to the Excess Prevalence of End-Stage Renal Disease in African Americans. The Journal of Clinical Hypertension 2001. 3:29–31. PMID: 11416679

37. Fan ZJ, Lackland DT, Lipsitz SR, Nicholas JS. The association of low birthweight and chronic renal failure among Medicaid young adults with diabetes and/or hypertension. Public health reports 2006.239–44. PMID: 16640145

38. Zidar N, Čavić MA, Kenda RB, Ferluga D. Unfavorable course of minimal change nephrotic syndrome in children with intrauterine growth retardation. Kidney international 1998. 54:1320–3. PMID: 9767550

39. Merlet-Bénichou C, Gilbert T, Muffat-Joly M, Lelièvre-Pégorier M, Leroy B. Intrauterine growth retardation leads to a permanent nephron deficit in the rat. Pediatric nephrology 1994. 8:175–80. PMID: 8018495

40. de Boer MP, IJzerman RG, de Jongh RT, Eringa EC, Stehouwer CD, Smulders YM, et al. Birth weight relates to salt sensitivity of blood pressure in healthy adults. Hypertension 2008. 52:625–30. doi: 10.1161/HYPERTENSIONAHA.107.101881 PMID: 18287343

41. Simonetti GD, Raio L, Surbek D, Nelle M, Frey FJ, Mohaupt MG. Salt sensitivity of children with low birth weight. Hypertension 2008. 52:625–30. doi: 10.1161/HYPERTENSIONAHA.107.101881 PMID: 18287343

42. Hughson M, Douglas-Denton R, Bertram J, Hoy W. Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. Kidney international 2006. 69:671–8. PMID: 16395270

43. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Ascherio AL, Stampfer MJ. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. Circulation 1996. 94:3246–50. PMID: 8989136

44. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. American journal of kidney diseases 1994. 23:171–5. PMID: 8311070

45. Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney International 2005. 68:S68–S77.

46. Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bulletin of the World Health Organization 1987. 65:663. PMID: 322602

47. Hinchliffe S, Sargent P, Howard C, Chan Y, Van Velzen D. Human intrauterine renal growth expressed in absolute number of glomeruli assessed by the disector method and Cavalieri principle. Laboratory investigation; a journal of technical methods and pathology 1991. 64:777–84. PMID: 2046329

48. Rodríguez MM, Gómez AH, Abitbol CL, Chandar JJ, Duara S, Zilleruelo GE. Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatric and developmental pathology 2004. 7:17–25. PMID: 15255031

49. Barker D, Osmond C, Golding J, Kuh D, Wadsworth M. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Bmj 1989. 298:564–7. PMID: 2495113

50. Yu V, Buka S, Zurakowski D, McCormick M, Brenner B, Jabs K. Relationship between birthweight and blood pressure in childhood. American journal of kidney diseases 1999. 33:253–60. PMID: 10023635

51. Schmidt IM, Chellakooty M, Boisen KA, Damgaard IN, Kai CM, Otgaard K, et al. Impaired kidney growth in low-birth-weight children: distinct effects of maturity and weight for gestational age. Kidney international 2005. 68:731–40. PMID: 16014509

52. Zidar N, Čavić M, Kenda RB, Koselj M, Ferluga D, an s. Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children. Nephron 1997. 79:28–32.

53. Palmer AC. Nutritional mediators of programmed cell death in the developing immune system. Advances in Nutrition: An International Review Journal 2011. 2:377–95.
54. Bellinger DL, Lubahn C, Lorton D. Retracted: Maternal and early life stress effects on immune function: relevance to immunotoxicology. Journal of Immunotoxicology 2008. 5:419–44. doi:10.1080/15476910802483415 PMID: 19404876

55. Björkstén B. Disease outcomes as a consequence of environmental influences on the development of the immune system. Current opinion in allergy and clinical immunology 2009. 9:185–9. doi:10.1097/ACI.0b013e3282abfc2 PMID: 19398907

56. Ferguson LR. Chronic inflammation and mutagenesis. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2010. 690:3–11. doi:10.1016/j.mrfmmm.2010.03.007 PMID: 20223251

57. Chandra R. Nutrition and immunology: from the clinic to cellular biology and back again. Proceedings of the Nutrition Society 1999. 58:681–3. PMID:10604203

58. Hoy WE, Samuel T, Mott SA, Kincaid-Smith PS, Fogo AB, Dowling JP, et al. Renal biopsy findings among Indigenous Australians: a nationwide review. Kidney international 2012. 82:1321–31. doi: 10.1038/ki.2012.307 PMID: 22932120

59. Ruggajo P, Skrunes R, Svarstad E, Skjærven R, Reisaæther AV, Vikse BE. Familial Factors, Low Birth Weight, and Development of ESRD: A Nationwide Registry Study. American Journal of Kidney Diseases 2015.

60. Kitajima T, Murakami M, Sakai O. Clinicopathological features in the Japanese patients with IgA nephropathy. Japanese journal of medicine 1983. 22:219–22. PMID: 6225895

61. D'AMICO G, IMBASCIATI E, DI BELGIOIOSO GB, BERTOLI S, FOGazzi G, FERRARIO F, et al. Idiopathic IgA mesangial nephropathy: clinical and histological study of 374 patients. Medicine 1985. 64:49–60. PMID: 3880853

62. Hood S, Velosa JA, Holley K, Donadio JV Jr. IgA-IgG nephropathy: predictive indices of progressive disease. Clinical nephrology 1981. 16:55–62. PMID: 7021031

63. Van der Peet J, Arisz L, Brentjens J, Marrink J, Hoedemaeker PJ. The clinical course of IgA nephropathy in adults. Clinical nephrology 1977. 8:335–40. PMID: 142595

64. Komatsu H, Fujimoto S, Yoshikawa N, Kitamura H, Sugiyama H. Clinical manifestations of Henoch–Schoenlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clinical and experimental nephrology 2015, 1–9.

65. Lee H, Kim DK, Oh K-H, Joo KW, Kim YS, Chae D-W, et al. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. American journal of nephrology 2013. 37:74–83. doi: 10.1159/000345960 PMID: 23348385

66. Barratt J, Feehally J. IgA nephropathy. Journal of the American Society of Nephrology 2005. 16:2088–97. PMID: 15930092

67. Hannedouche T, Chauveau P, Kalou F, Alouze G, Lacour B, Jungers P. Factors affecting progression in advanced chronic renal failure. Clinical nephrology 1993. 39:312–20. PMID: 8334758

68. Ji H, Zheng W, Menini S, Pesce C, Kim J, Wu X, et al. Female protection in progressive renal disease is associated with estradiol attenuation of superoxide production. Gender medicine 2007. 4:56–71. PMID: 17584628

69. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. American journal of kidney diseases 1995. 25:515–33. PMID: 7702046

70. Treluyer J, Merle Y, Tonnelier S, Rey E, Pons G. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrobial agents and chemotherapy 2002. 46:1381–7. PMID: 11959572

71. Botha J, Du Preez M, Miller R, Adhikari M. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. European journal of clinical pharmacology 1998. 53:337–41. PMID: 9516033

72. Vikse BE, Bostad L, Aasand K, Lysebo DE, Iversen BM. Prognostic factors in mesangioproliferative glomerulonephritis. Nephrology Dialysis Transplantation 2002. 17:1603–13.

73. Radford M, Donadio JV, Bergstrahl EJ, Grande JP. Predicting renal outcome in IgA nephropathy. Journal of the American Society of Nephrology 1997. 8:199–207. PMID: 9048338